These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 8874986)

  • 1. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
    Rackley CE
    Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
    Furberg CD; Pitt B; Byington RP; Park JS; McGovern ME
    Am J Cardiol; 1995 Sep; 76(9):60C-63C. PubMed ID: 7572689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():257-63. PubMed ID: 9211018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.
    Plosker GL; McTavish D
    Drugs; 1995 Aug; 50(2):334-63. PubMed ID: 8521762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
    Bjelajac A; Goo AK; Weart CW
    Ann Pharmacother; 1996 Nov; 30(11):1304-15. PubMed ID: 8913414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S).
    Tonkin AM
    Am J Cardiol; 1995 Sep; 76(9):107C-112C. PubMed ID: 7572678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.
    Probstfield JL; Margitic SE; Byington RP; Espeland MA; Furberg CD
    Am J Cardiol; 1995 Sep; 76(9):47C-53C. PubMed ID: 7572686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L; Kramsch DM; Azen SP; DeMets D; DeBoer LW; Hwang I; Vailas L; Hirsch LJ; Mack WJ; DeBoer L
    Online J Curr Clin Trials; 1992 Oct; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).
    Kjekshus J; Pedersen TR
    Am J Cardiol; 1995 Sep; 76(9):64C-68C. PubMed ID: 7572690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative tolerability of the HMG-CoA reductase inhibitors.
    Farmer JA; Torre-Amione G
    Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study).
    Vigen C; Hodis HN; Selzer RH; Mahrer PR; Mack WJ
    Am J Cardiol; 2005 Jun; 95(11):1277-82. PubMed ID: 15904629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease.
    Watanabe K; Sugiyama S; Kugiyama K; Honda O; Fukushima H; Koga H; Horibata Y; Hirai T; Sakamoto T; Yoshimura M; Yamashita Y; Ogawa H
    J Am Coll Cardiol; 2005 Dec; 46(11):2022-30. PubMed ID: 16325036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.